05.21.25 -- Lilly's CEO Building On The Trump Agenda

Subcutaneous (Sub-Q) delivery offers self-administration and fewer hospital visits but is challenging for high-dose biologics. Nanoform developed a concentrated, non-aqueous Sub-Q IgG1 suspension using its patented dry particle platform. The study evaluated particle size impact, formulation properties, protein quality, and stability, with pharmacokinetic studies ongoing. Key topics include Sub-Q benefits, Nanoform’s dry particle process, and non-aqueous suspension formulation. Click here to learn more.

If you’re launching an international clinical trial, consider the noteworthy benefits of partnering with an in-country depot, including increased efficiency, reduced costs, and reliable access to raw materials.

Physiologically based pharmacokinetic (PBPK) modeling advancements are helping drug sponsors mitigate risk in preclinical and clinical studies through early identification of poor absorption properties.

Executive Director of Pharmaceutical Sciences Srinivasan Shanmugam, Ph.D., discusses pediatric patient compliance, regulations impacting trial access, excipients within formulations, and more.

Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report”. The report identifies CDMOs possibly impacted by events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.

Explore advanced approaches to designing robust amorphous formulations and optimizing spray drying processes tailored specifically to difficult-to-formulate compounds.

By leveraging the country's regulatory advantages and partnering with a New Zealand-based CDMO, international companies can accelerate approvals and navigate the regulatory pathway with ease.

Uncover how bioavailability of poorly soluble APIs can be improved and patient compliance enhanced by reducing the size or number of tablets that a patient must take to achieve the required dose.

Review our full range of support services to streamline manufacturing processes through to the commercialization of aseptic and lyophilized products.

Consider our integrated GMP manufacturing services for oral dosage forms with a full complement of analytical development and testing capabilities for your next project.

Discover cost-efficient, global solutions for process development and preclinical manufacturing — partner with a trusted network to simplify your outsourcing needs.